EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access

Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study

Collin M Blakely iD, Anatoly Urisman iD, Matthew A Gubens, Claire K Mulvey, Greg M Allen iD, Stephen C Shiboski iD, Julia K Rotow, Turja Chakrabarti iD, D Lucas Kerr iD, Jacqueline V Aredo iD, Bianca Bacaltos iD, Megan Gee und 12 weitere

Journal of Clinical Oncology · 10.09.2024 · 42 (26) · 3105-3114

DOI: 10.1200/jco.24.00071 ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.09.2024. Verfasst von Collin M Blakely und 23 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, University of California, San Francisco, San Francisco, CA. Hauptthemen laut MEDLINE: Acrylamides, Carcinoma, Non-Small-Cell Lung, Aniline Compounds, Lung Neoplasms. Die Arbeit wurde bisher 79-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE To assess the safety and efficacy of the third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor osimertinib as neoadjuvant therapy in patients with surgically resectable stage I-IIIA EGFR-mutated non–small cell lung cancer (NSCLC). PATIENTS AND METHODS This was a multi-institutional phase II trial of neoadjuvant osimertinib for patients with surgically resectable stage I-IIIA (American Joint Committee on Cancer [AJCC] V7) EGFR-mutated (L858R or exon 19 deletion) NSCLC (ClinicalTrials.gov identifier: NCT03433469 ). Patients received osimertinib 80 mg orally once daily for up to two 28-day cycles before surgical resection. The primary end point was major pathological response (MPR) rate. Secondary safety and efficacy end points were also assessed. Exploratory end points included pretreatment and post-treatment tumor mutation profiling. RESULTS A total of 27 patients were enrolled and treated with neoadjuvant osimertinib for a median 56 days before surgical resection. Twenty-four (89%) patients underwent subsequent surgery; three (11%) patients were converted to definitive chemoradiotherapy. The MPR rate was 14.8% (95% CI, 4.2 to 33.7). No pathological complete responses were observed. The ORR was 52%, and the median DFS was 40.9 months. One treatment-related serious adverse event (AE) occurred (3.7%). No patients were unable to undergo surgical resection or had surgery delayed because of an AE. The most common co-occurring tumor genomic alterations were in TP53 (42%) and RBM10 (21%). CONCLUSION Treatment with neoadjuvant osimertinib in surgically resectable (stage IA-IIIA, AJCC V7) EGFR-mutated NSCLC did not meet its primary end point for MPR rate. However, neoadjuvant osimertinib did not lead to unanticipated AEs, surgical delays, nor result in a significant unresectability rate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcrylamidesCarcinoma, Non-Small-Cell LungAniline CompoundsLung NeoplasmsErbB ReceptorsNeoadjuvant TherapyMutationHumansFemaleMaleMiddle AgedAgedNeoplasm StagingAdultProtein Kinase InhibitorsAntineoplastic AgentsIndolesPyrimidines

Substanzen

osimertinibAcrylamidesAniline CompoundsErbB ReceptorsEGFR protein, humanProtein Kinase InhibitorsAntineoplastic AgentsIndolesPyrimidines

Autor:innen und Institutionen

  • Department of Medicine, University of California, San Francisco, San Francisco, CA.
  • Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA.
  • Department of Pathology, University of California, San Francisco, San Francisco, CA.
  • Department of Epidemiology and Biostatistics, University of California, San Francisco, San Francisco, CA.
  • Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA.
  • Institute for Human Genetics, University of California, San Francisco, San Francisco, CA.

ORCID-Profile: Collin M Blakely, Anatoly Urisman, Greg M Allen, Stephen C Shiboski, Turja Chakrabarti, D Lucas Kerr, Jacqueline V Aredo, Bianca Bacaltos, Kirk D Jones, Dara L Aisner, Tejas Patil, Erin L Schenk, Trever G Bivona, Johannes R Kratz

Förderung

  • NCI NIH HHS

Zitieren

APA

Blakely, C. M., Urisman, A., Gubens, M. A., Mulvey, C. K., Allen, G. M., Shiboski, S. C., Rotow, J. K., Chakrabarti, T., Kerr, D. L., Aredo, J. V., Bacaltos, B., Gee, M., Tan, L., Jones, K. D., Devine, W. P., Doebele, R. C., Aisner, D. L., Patil, T., Schenk, E. L., …, & Jablons, D. M. (2024). Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study. Journal of Clinical Oncology, 42(26), 3105-3114. https://doi.org/10.1200/jco.24.00071

Vancouver

Blakely CM, Urisman A, Gubens MA, Mulvey CK, Allen GM, Shiboski SC, et al. Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study. Journal of Clinical Oncology. 2024;42(26):3105-3114. doi:10.1200/jco.24.00071

BibTeX
@article{Blakely2024,
  author = {Blakely, Collin M and Urisman, Anatoly and Gubens, Matthew A and Mulvey, Claire K and Allen, Greg M and Shiboski, Stephen C and Rotow, Julia K and Chakrabarti, Turja and Kerr, D Lucas and Aredo, Jacqueline V and Bacaltos, Bianca and Gee, Megan and Tan, Lisa and Jones, Kirk D and Devine, W Patrick and Doebele, Robert C and Aisner, Dara L and Patil, Tejas and Schenk, Erin L and Bivona, Trever G and Riess, Jonathan W and Coleman, Melissa and Kratz, Johannes R and Jablons, David M},
  title = {Neoadjuvant Osimertinib for the Treatment of Stage I-IIIA Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer: A Phase II Multicenter Study},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {26},
  pages = {3105--3114},
  doi = {10.1200/jco.24.00071}
}
Kostenlos starten →